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Surgical removal of the prostate and seminal vesicles has a high
chance of cure when prostate cancer is conﬁned to the prostate.
High-risk features, such as the presence of extraprostatic extension
(Stage pT3a or pT3b) and/or positive surgical margins found at the
time of surgery increase the risk of the cancer recurring. Despite a
stage shift to earlier cancer stages and lower tumor volumes for
prostate cancer, pathologically advanced disease is detected at
radical prostatectomy (RP) in 38e52% of patients.1
The current study enrolled 53menwith prostate cancer of path-
ological adverse characteristics who had undergone RP, and
compared outcomes of early (< 3 months) and delayed (3e12
months) adjuvant radiotherapy (ART) after RP. The results showed
trends of early ART improving 5-year biochemical-free survival, less
salvage hormonal therapy, and more urethral stricture; however,
there were no statistically signiﬁcant differences.
On the issue of ART for men with histologically conﬁrmed inva-
sive prostate adenocarcinoma without regional lymph node
involvement or distantly metastatic disease, who have undergone
RP, three large randomized trials by the Southwest Oncology
Group,2 Arbeitsgemeinschaft Radiologische Onkologie,3 and the
European Organization for Research and Treatment of Cancer4
have now reported on the beneﬁcial outcome of ART in patients
with pathological risk factors after prostatectomy. These thee trials
enrolled 1815 men who were randomized to either adjuvant
external beam radiotherapy in the immediate postoperative period
after prostatectomy, or to observation with therapies (including
radiotherapy, androgen deprivation therapy, and other therapies)
held in reserve for salvage radiotherapy (SRT). Median follow-up
time ranged from 4.5 years to 12.6 years. According to these trials,
ART following prostatectomy improved local control and biochem-
ical progression-free survival. It did not affect overall survival, pros-
tate cancer-speciﬁc mortality, or reduced metastasis at 5 years, but
improved survival and reduced metastatic disease at 10 years.5 The
results of this article seemed to be similar, but could not reach a sta-
tistically signiﬁcant difference between the two groups. This might
be due to the limited case numbers.http://dx.doi.org/10.1016/j.urols.2015.11.005
1879-5226/Copyright © 2015, Taiwan Urological Association. Published by Elsevier Ta
creativecommons.org/licenses/by-nc-nd/4.0/).The primary reasons cited for choosing selective SRT over ART
include the perceived toxicity of immediate post-RP radiotherapy,
the potential overtreatment of patients with ART who may not
have had a recurrence after RP, the importance of delaying radio-
therapy to allow time for recovery of urinary and sexual function
after RP, and the presumed equivalence of ART and SRT strategies
for cancer control. According to these trials, ART increased more
acute and late gastrointestinal toxicity, urinary stricture, and incon-
tinence. However, it did not increase erectile dysfunction or
degrade quality of life. Kowalczyk et al6 also reported the Surveil-
lance, Epidemiology and End Results-Medicare data from 1995 to
2007, identifying 963 men with pT3N0 disease receiving early (<
4 months) versus delayed (4e12 months) ART after RP; ART per-
formed after 9 months was associated with fewer urethral stric-
tures. Trends of urethral stricture were also noted at early ART in
this article.
According to current evidence, for menwho have undergone an
RP and who have a longer life expectancy, radiotherapy should be
considered for those with high-risk features following RP. Given
the relevance of toxicity risk and the inﬂuence of radiation timing,
it is important to accumulate more evidence. As such, it would be
helpful to make a decision on whether to adopt early or delayed
post-RP radiotherapy.
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